Jr. Michael Conick Hanley
CIK 1791413 · CHIEF OPERATING OFFICER · last filed 2026-02-13
Jr. Michael Conick Hanley is a CHIEF OPERATING OFFICER who has filed 11 SEC Form 4 insider transactions across 2 companies since 2019. The most recent filing, for ANRO, was dated Feb 13, 2026. Across all open-market trades the lifetime net is +$20.0K, making them a net buyer over the disclosed history.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$0
2
11
$20.0K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ANRO | CHIEF OPERATING OFFICER | — | $21.47 | — | $0 | 4 | 2026-02-13 |
| Spyre Therapeutics, Inc. (AGLE) Delisted | Chief Business Officer | 36,200 | $12.01 | $434.8K | $20.0K | 7 | 2023-02-24 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-02-13 | ANRO | Grant (A) | — | $0 | EDGAR |
| 2025-07-08 | ANRO | Mixed | — | $0 | EDGAR |
| 2025-02-07 | ANRO | Grant (A) | — | $0 | EDGAR |
| 2024-05-22 | ANRO | Grant (A) | — | $0 | EDGAR |
| 2023-02-24 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-08-25 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | Spyre Therapeutics, Inc. (AGLE) Delisted | Buy (P) | +28,200 | $20.0K | EDGAR |
| 2022-02-22 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-02-19 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-02-19 | Spyre Therapeutics, Inc. (AGLE) Delisted | Grant (A) | — | $0 | EDGAR |